Fyarro Now Available for Malignant Perivascular Epithelioid Cell Tumor
Fyarro has also been added to the NCCN Guidelines as the only preferred treatment regimen for malignant PEComa.
Fyarro has also been added to the NCCN Guidelines as the only preferred treatment regimen for malignant PEComa.
The new approvals include Besremi, Fyarro, Livtencity, Voxzogo, and Vuity.
The approval of Fyarro, an mTOR inhibitor, was based on data from the phase 2 AMPECT study, which included 34 adults with advanced malignant PEComa.
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
Risks increased for skin cancer and GI, pulmonary, infectious, hematologic adverse events
Strontium89 (Strontium Chloride Sr-89 injection), a radiopharmaceutical indicated for the relief of bone pain in patients with painful skeletal metastases, has been made available by Q BioMed.
The FDA has granted accelerated approval to Tazverik™ (tazemetostat tablets; Epizyme) for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
The FDA has granted Priority Review to the Biologics License Application (BLA) of belantamab mafodotin (GSK2857916; GlaxoSmithKline) for the treatment of patients with relapsed or refractory multiple myeloma whose prior therapy included an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody.
This slideshow shows drug information for Rozlytrek. Click here for the complete Rozlytrek monograph.
The approval was based on data from a phase 3 study which compared induction and consolidation treatment with Darzalex in combination with bortezomib, thalidomide and dexamethasone to treatment with bortezomib, thalidomide, and dexamethasone.